Search hospitals > North Carolina > Huntersville

Carolina BioOncology Institute

Claim this profile
Huntersville, North Carolina 28078
Global Leader in Solid Tumors
Global Leader in Tumors
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
94 reported clinical trials
2 medical researchers
Photo of Carolina BioOncology Institute in HuntersvillePhoto of Carolina BioOncology Institute in HuntersvillePhoto of Carolina BioOncology Institute in Huntersville

Summary

Carolina BioOncology Institute is a medical facility located in Huntersville, North Carolina. This center is recognized for care of Solid Tumors, Tumors, Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. Carolina BioOncology Institute is involved with conducting 94 clinical trials across 72 conditions. There are 2 research doctors associated with this hospital, such as John Powderly, M.D. and John D. Powderly II, MD.

Area of expertise

1Solid Tumors
Global Leader
Carolina BioOncology Institute has run 49 trials for Solid Tumors. Some of their research focus areas include:
Stage IV
Stage III
PD-L1 positive
2Tumors
Global Leader
Carolina BioOncology Institute has run 42 trials for Tumors. Some of their research focus areas include:
Stage IV
Stage III
ALK positive

Top PIs

Clinical Trials running at Carolina BioOncology Institute

Solid Tumors
Tumors
Cancer
Prostate Cancer
Pancreatic Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Ovarian Cancer
Adenocarcinoma
Image of trial facility.

NUV-1511

for Solid Tumors

NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Recruiting1 award Phase 1 & 2
Image of trial facility.

AU-007

for Advanced Cancer

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w)
Recruiting1 award Phase 1 & 28 criteria
Image of trial facility.

ABBV-303 + Budigalimab

for Solid Tumors

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy and in combination with budigalimab, (ABBV-181). ABBV-303 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-303 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 181 adult participants will be enrolled in the study across sites worldwide. In Part A, ABBV-303 will be intravenously (IV) infused in escalating doses as a monotherapy in participants with relapsed (R)/refractory (R) solid tumors, R/R non-small cell lung cancer (NSCLC), R/R renal cell carcinoma (RCC), R/R head and neck squamous cell carcinoma (HNSCC), or R/R tissue agnostic participants with mesenchymal epithelial transition. In Part B, ABBV-303 in combination with budigalimab will be IV infused in participants with R/R solid tumors or NSCLC. The estimated duration of the study is up to 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Recruiting1 award Phase 14 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Carolina BioOncology Institute?
Carolina BioOncology Institute is a medical facility located in Huntersville, North Carolina. This center is recognized for care of Solid Tumors, Tumors, Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. Carolina BioOncology Institute is involved with conducting 94 clinical trials across 72 conditions. There are 2 research doctors associated with this hospital, such as John Powderly, M.D. and John D. Powderly II, MD.